Detalhe da pesquisa
1.
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.
Future Oncol
; 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38682560
2.
Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results.
Oncologist
; 28(9): 825-e817, 2023 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37196069
3.
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.
BJU Int
; 132(2): 170-180, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36748180
4.
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer.
J Pathol
; 256(1): 108-118, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34611919
5.
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
Lancet Oncol
; 23(1): 53-64, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34838156
6.
Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
Oncologist
; 26(5): e838-e846, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33524191
7.
Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival.
World J Urol
; 39(12): 4363-4371, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196758
8.
Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors.
Eur J Clin Pharmacol
; 76(4): 579-587, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31932871
9.
Skin toxicity of enfortumab vedotin: Proposal of a specific management algorithm.
J Eur Acad Dermatol Venereol
; 38(1): e99-e101, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37607297
10.
Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.
Mod Pathol
; 31(8): 1270-1281, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29467478
11.
[Management of metastatic bladder cancer]. / Prise en charge des tumeurs de vessie métastatiques.
Rev Prat
; 64(10): 1405-7, 2014 Dec.
Artigo
em Francês
| MEDLINE | ID: mdl-25668832
12.
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 14(2): 149-58, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23306100
13.
Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials.
Eur Urol
; 85(3): 293-300, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36849297
14.
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
JNCI Cancer Spectr
; 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38627238
15.
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.
J Clin Oncol
; 42(12): 1415-1425, 2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38261969
16.
[Chemotherapy in castrate-resistant metastatic prostate cancer]. / Chimiothérapie dans le cancer de la prostate métastatique résistant a la castration.
Rev Prat
; 63(4): 511-4, 2013 Apr.
Artigo
em Francês
| MEDLINE | ID: mdl-23682481
17.
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer.
Cancers (Basel)
; 15(1)2023 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36612311
18.
Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients with No Progression and with No More than Five Residual Metastatic Lesions Following First-Line Systemic Therapy: A Retrospective Analysis.
Cancers (Basel)
; 15(4)2023 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36831503
19.
The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis.
Int J Surg Pathol
; 31(2): 157-166, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35466737
20.
Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
Anticancer Drugs
; 23(1): 141-2, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21934600